Siddhartha Roychoudhury
Company: Astellas Pharma
Job title: Asset Leader, Immuno Oncology Development
Seminars:
Panel Discussion: Insights into Claudin Biology & its Impact On Cancer Progression 9:30 am
Understanding the dynamic expression patterns of Claudin 18.2, 6, and 9 in different cancer stages and the implications for therapeutic targeting Outlining the role of claudin proteins in tumor microenvironment interactions and how these interactions influence cancer progression and metastasis Identifying how understanding claudin biology can inform clinical strategies and improve therapeutic outcomes, including the…Read more
day: Conference Day 2
Panel Discussion: Clinical Advancements in Claudin-Targeted ADCs, Bispecifics, & CAR-T Therapies 11:00 am
Deep diving into the latest advancements and clinical outcomes of ADCs targeting Claudin 18.2 and Claudin 6, with a focus on engineering, payload optimization, and toxicity management specific to claudin targets Examining the role and efficacy of bispecific antibodies in enhancing the immune response against claudin-expressing tumors, supported by insights from preclinical and clinical data…Read more
day: Conference Day 1
Delving into Claudin Biology & Translational Success in Claudin-Targeted Therapies 9:25 am
day: Conference Day 2
Chair’s Closing Remarks 1:00 pm
day: Conference Day 2